The Leading Scholar program awards various levels of scholarships recognizing the leadership skills and academic success of applicants. While a select number of applicants will be invited to campus ...

A phase 3 trial of Scholar Rock’s spinal muscular atrophy (SMA) candidate has hit its primary endpoint, sparking a 200%-plus premarket surge in the biotech’s stock price. Investors went wild despite ...

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein ...

Scholar Rock contends its experimental drug for spinal muscular atrophy can achieve what none of the currently available therapies can do to treat this rare disease. After positive data from a pivotal ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings in ...

The Kellogg Executive Scholar Certificate gives you the opportunity to earn a credential from a world-class business school, create a personalized leadership development path aligned with your unique ...

Scholar Rock's Apitegromab BLA received a CRL due to issues at Catalent Indiana's facility, unrelated to the drug itself. Scholar Rock is working with Catalent to address FDA observations and plans to ...

Posts from this author will be added to your daily email digest and your homepage feed. is a NYC-based AI reporter and is currently supported by the Tarbell Center for AI Journalism. She covers AI ...